Evaluation of the Safety of 10-Day Daily Bucco-Oral Administration of Transfer Factor in Healthy Adult Human Subjects

The primary objective of this study is to evaluate the **safety** of a 10-day daily bucco-oral administration of Transfer Factor in healthy adult human subjects. This assessment is clinically relevant as it aims to ensure that the administration of Transfer Factor does not pose any adverse effects on individuals with normal health status. The study focuses on conditions with decreased immunity, such as recurrent and chronic viral infections, where Transfer Factor is used to enhance immune function.

The clinical trial involves **healthy subjects** with a focus on enhancing immunity, particularly in cases of recurrent and chronic viral infections. The study population includes both male and female participants, with an age range of 18 to 65 years. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their general health status, ensuring they are free from significant medical conditions that could interfere with the study's objectives. Lifestyle considerations such as diet, physical activity, and habits were not specified. Key inclusion or exclusion criteria were not detailed by the sponsor.

The clinical trial is designed to assess the safety of a 10-day daily bucco-oral administration of **Transfer Factor** in healthy adult human subjects. This trial is a Phase 1 study, which is typically the first stage of testing in human subjects and focuses on evaluating safety, dosage, and side effects. The trial is expected to commence recruitment on September 28, 2024, and conclude by December 19, 2024. The study employs a randomized, double-blind, controlled design to ensure unbiased results and to compare the effects of the investigational product against a placebo or standard treatment.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be enrolled in the study and will begin the 10-day treatment period. During this period, regular follow-up visits will be scheduled to monitor the participants' health, adherence to the treatment regimen, and any adverse events. These visits are crucial for collecting data on the safety and tolerability of the treatment.

The end-of-study visit will occur shortly after the completion of the treatment period. This visit will involve a final evaluation of the participants' health status and the collection of any remaining data required for the study's analysis. The expected length of participant involvement is approximately three months, including the screening, treatment, and follow-up phases. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to ensure the safety and well-being of participants while providing valuable data on the investigational product's safety profile.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and methodologies employed in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is September 28, 2024, with an anticipated end date of December 19, 2024. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. The methods for measuring, collecting, and analyzing efficacy data are not specified, but such trials generally employ validated scales, laboratory tests, or patient-reported outcomes to gather relevant data. The absence of detailed endpoints suggests that the primary focus may be on safety and tolerability, with efficacy being a secondary consideration. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the collected data.